Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

BACKGROUND: The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed in pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression. METHODS: We present t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortellini, Alessio, Ricciuti, Biagio, Tiseo, Marcello, Bria, Emilio, Banna, Giuseppe L, Aerts, Joachim GJV, Barbieri, Fausto, Giusti, Raffaele, Cortinovis, Diego L, Migliorino, Maria R, Catino, Annamaria, Passiglia, Francesco, Torniai, Mariangela, Morabito, Alessandro, Genova, Carlo, Mazzoni, Francesca, Di Noia, Vincenzo, Signorelli, Diego, Gelibter, Alain, Occhipinti, Mario Alberto, Rastelli, Francesca, Chiari, Rita, Rocco, Danilo, Inno, Alessandro, De Tursi, Michele, Di Marino, Pietro, Mansueto, Giovanni, Zoratto, Federica, Grossi, Francesco, Filetti, Marco, Pizzutilo, Pamela, Russano, Marco, Citarella, Fabrizio, Cantini, Luca, Targato, Giada, Nigro, Olga, Ferrara, Miriam G, Buti, Sebastiano, Scodes, Simona, Landi, Lorenza, Guaitoli, Giorgia, Della Gravara, Luigi, Tabbò, Fabrizio, Ricciardi, Serena, De Toma, Alessandro, Friedlaender, Alex, Petrelli, Fausto, Addeo, Alfredo, Porzio, Giampiero, Ficorella, Corrado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574933/
https://www.ncbi.nlm.nih.gov/pubmed/33077515
http://dx.doi.org/10.1136/jitc-2020-001403

Ejemplares similares

Ejemplares similares